Williams-Salmon v. Raheja

2022 Ohio 1675
CourtOhio Court of Appeals
DecidedMay 19, 2022
Docket110856 & 110928
StatusPublished
Cited by1 cases

This text of 2022 Ohio 1675 (Williams-Salmon v. Raheja) is published on Counsel Stack Legal Research, covering Ohio Court of Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Williams-Salmon v. Raheja, 2022 Ohio 1675 (Ohio Ct. App. 2022).

Opinion

[Cite as Williams-Salmon v. Raheja, 2022-Ohio-1675.]

COURT OF APPEALS OF OHIO

EIGHTH APPELLATE DISTRICT COUNTY OF CUYAHOGA

MARILYN WILLIAMS-SALMON :

Plaintiff-Appellee, : Nos. 110856 and 110928 v. :

DEEPAK RAHEJA, M.D., ET AL., :

Defendants-Appellants. :

JOURNAL ENTRY AND OPINION

JUDGMENT: AFFIRMED RELEASED AND JOURNALIZED: May 19, 2022

Civil Appeal from the Cuyahoga County Court of Common Pleas Case No. CV-20-928108

Appearances:

Ryan, LLP, Thomas P. Ryan and Daniel J. Ryan, for appellee.

Squire Patton Boggs, LLP and Colin R. Jennings, for appellant Gregory Hayslette.

Donald J. Malarcik and John P. Stiles, for appellant Frank Mazzucco.

CORNELIUS J. O’SULLIVAN, JR., J.:

Defendants-appellants, Gregory Hayslette (“Hayslette”) and Frank

Mazzucco (individually “Mazzucco,” collectively “appellants”) appeal the trial court’s interlocutory order granting plaintiff-appellee’s Marilyn Williams-Salmon’s

(“appellee”) motion to compel. After a thorough review of the law and facts, we

affirm.

I. Procedural History and Facts

This civil suit emanates from a course of treatment for appellee wherein

she was prescribed prescription medication by her doctor, Deepak Raheja, M.D.

(“Dr. Raheja”). It was alleged that appellee received medical treatment from

Dr. Raheja between 2010-2016. Appellee claims at some point during this

treatment, she was misdiagnosed with a neurological disorder known as

Pseudobulbar Affect (“PBA”). Appellee maintains that she was unaware of her

misdiagnosis until November 2019, when she was informed by the United States

Attorney’s Office that she was a potential victim of an illegal kickback scheme. This

scheme allegedly involved Avanir Pharmaceuticals, Inc. (“Avanir”) and its

employees providing illegal incentives to Dr. Raheja in exchange for prescribing

medications to patients, like appellee, for conditions unsupported by their

presenting symptoms. Specifically, appellee contends that she was prescribed a

medication called Nuedexta, which is sold by Avanir. Hayslette worked for Avanir

as a pharmaceutical sales representative responsible for the marketing of Nuedexta.

Mazzucco was his supervisor. Appellee alleges she suffered numerous personal

injuries due to appellants’ conduct.

In 2019, appellants, among others, were charged in an 83-count

indictment in federal court. The indictment alleged, among other crimes, that the appellants had violated the federal Anti-Kickback Statute, 42 U.S.C. 1320a-

7b(b)(1)(B) and 42 U.S.C. 1320a-7b(b)(2)(B).1

Appellee filed the underlying action against appellants, Dr. Raheja and

Avanir, on January 21, 2020, alleging: medical malpractice against Dr. Raheja;

medical battery and lack of informed consent against Dr. Raheja; negligence against

all defendants; civil recovery for a criminal act, R.C. 2307.60, against all defendants;

Ohio corrupt practices act, R.C. 2923.34, against all defendants; and civil conspiracy

against all defendants.2

The court conducted a status conference on December 17, 2020, and

ordered the parties to complete fact discovery by August 31, 2021. In December

2020, appellee filed an amended complaint, attaching an affidavit of merit

pursuant to Civ.R. 10(D)(2); the amended complaint included the same parties,

allegations, and prayers for relief as the original pleading. Appellee filed motions

to compel discovery against each appellant in June 2021, those motions were

granted by the court on September 15, 2021. This timely appeal follows.

A. The Discovery Dispute

1 In March 2022, Hayslette pled guilty to Count 1, Conspiracy to Solicit, Receive, Offer and Pay Healthcare Kickbacks in violation of 18 U.S.C. 371 and is awaiting sentencing. Trial for Mazzucco and Dr. Raheja is set for October 2022. Dr. Raheja is not a party to this appeal.

2 In February 2020, Avanir removed the case to federal court asserting that federal court had jurisdiction under 28 U.S.C. 1331. In March 2020, appellee filed to remand the case back to state court; the court granted her motion. Williams- Salmon v. Avanir Pharmaceuticals, Inc., N.D.Ohio No. 1:20 CV 419, 2020 U.S. Dist. LEXIS 136347, 17 (July 31, 2020). In March 2021, appellee issued discovery requests to both appellants,

which included interrogatories, requests for production of documents, and requests

for admissions.

i. Interrogatories

Appellee’s interrogatories asked each appellant to identify and/or

confirm:

1. Witnesses, including expert witnesses. (INT #1-2, 5)

2. Exhibits to be used at trial. (INT #3)

3. Persons who assisted appellants in preparing discovery. (INT #4)

4. Name, current and former addresses, employers. (INT #5, 8, 9)

5. Proper service of complaint. (INT #6)

6. Employment history with Avanir. (INT #10-12, 14-15)

7. Sources of income. (INT #13)

8. Statements given to Avanir or Avanir investigators. (INT #16, 19)

9. Witnesses in federal criminal case. (INT #17-18)

10. Civil and criminal case history. (INT #20-21)

11. Witness statements in connection with criminal case. (INT #22)

12. Insurance coverage and any communications with insurer. (INT #23)

ii. Request for Production of Documents

Appellee’s request for production of documents requested copies of:

1. Documents to be used in trial. (RFP #1)

2. Appellee’s medical records and bills. (RFP #2-4) 3. Appellants’ curriculum vitae. (RFP #5)

4. Expert reports. (RFP #6-9)

5. Photographs or video recordings of appellee. (RFP #10)

6. Communications among co-defendants. (RFP #11-13)

7. Communications with other named individuals, including Avanir. (RFP #14-30)

8. Contracts with Avanir. (RFP #31-33)

9. Avanir training manuals, assessments, or compliance documents. (RFP #34)

10. Reports, recordings, and video recordings related to services provided to appellee. (RFP #35)

11. Documents received from the government during appellants’ criminal matter. (RFP #36-37)

12. Payments received from Avanir. (RFP #38)

13. Insurance coverage and any communications with appellants’ insurance companies. (RFP #39-42)

14. Communication between appellants and appellee. (RFP #43)

14. Account profile sheets demonstrating the number of patients seen by Dr. Raheja from 2011 to 2016. (RFP #44)

15. Avanir’s internal investigation report and file. (RFD#45-47)

16. Documents concerning Avanir’s Speaker’s Bureau Program, including the training and communication from lawyers, managers, and compliance personnel. (RFP #47-49, 56)

17. Communications with Avanir’s compliance or legal department. (RFP #50)

18. Documents representing deleted text messages of Avanir employees. (RFP #51)

19. Government subpoenas. (RFP #52-53) 20. Notes from the September 23, 2019, meeting of Avanir’s board of directors. (RFP #54-55)

21. Documents related to and copies of various research reports and studies. (RFP #57, 59)

22.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

V.T. Larney, Ltd. v. Ohio Civ. Rights Comm.
2023 Ohio 3123 (Ohio Court of Appeals, 2023)

Cite This Page — Counsel Stack

Bluebook (online)
2022 Ohio 1675, Counsel Stack Legal Research, https://law.counselstack.com/opinion/williams-salmon-v-raheja-ohioctapp-2022.